ENAGenomicsUniversity of Nebraska Medical Centerhttps://www.ebi.ac.uk/ena/browser/view/PRJNA1263879Parkinson's disease is a progressive neurodegenerative disorder that affects movement, muscle control, and balance, with limited therapeutic options. Natural therapies, including lifestyle changes, probiotics, muscle relaxants, and colostrum, have received recent attention for symptom relief. Of these, colostrum, particularly the extracellular vesicles it produces, holds specific promise. Herein, colostrum EVs were purified and then administered to the MPTP PD model, demonstrating both anti-inflammatory and neuroprotective disease outcomes. EV-treated MPTP-intoxicated animals reduced microglial activation and mitigated neurodegeneration. RNA sequencing and transcriptomic analysis showed reduced immunocyte recruitment, activation, and neurotoxin production in the diseased brain. Canonical inflammasome activation, pro-inflammatory cytokines, and chemokine expression were controlled. EV treatments were associated with reduced immune-regulatory transcription factors. Concomitantly, regulatory T cell-associated adaptive immune responses were increased. Multiple EV miR immune regulatory cargos supported associations between the control of neuroinflammation and nigral preservation. Together, the results demonstrate the potential of colostrum EVs as future PD therapeutic agents.ENAfalseColostrum Extracellular Vesicles are Neuroprotective In a Parkinson's Disease Model2025-06-192025-06-19PRJNA1263879